Research and regulatory agencies add credibility to the rapidly growing CBD market

Twitter icon

The cannabis marketplace has become one of the fastest growing global industries, as the rapid expansion of the cannabis market is largely due to the ongoing legalization efforts in many countries. The medical cannabis sector currently accounts for a majority of the market value due to the legal hindrances imposed on recreational cannabis. Medical cannabis, on the other hand, is generally more accepted among virtually every country and now, many governments are adopting medical cannabis legislation in order to use cannabis as an alternative to traditional medication. Furthermore, research and studies recently conducted have also linked cannabis to providing consumers with therapeutic effects which relieve a wide range of medical symptoms. The development of the industry has also introduced new cannabis-based products for medicinal uses. Traditionally, most consumers smoked cannabis, however, cannabis is now being converted into oils, capsules, edibles, vapor, creams, and powders. Each variation is used for different purposes, for instance, users apply cannabis-based creams to suppress pain on specific body parts. On the other hand, consumers can smoke oil or vapor to treat major medical conditions such as cancer, Alzheimer's, Crohn's disease, multiple sclerosis, and epilepsy. According to data compiled by Genesis Market Insights, the global marijuana market was valued at USD 17.18 Billion in 2017. By the year 2023, the market is expected to grow to USD 58.90 Billion while registering a CAGR of 22.91%. Pressure BioSciences, Inc. (OTC: PBIO), Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB), Village Farms International, Inc. (NASDAQ: VFF) (TSX: VFF), Green Thumb Industries Inc. (OTC: GTBIF) (CSE: GTII), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)

The U.S. Food and Drug Administration recently approved the first cannabis-derived drug, Epidiolex, which is used to treat epilepsy in children. The cannabis plant is comprised of over 104 different cannabinoids and around 750 different chemicals, yet, the FDA has only approved a CBD-based drug so far. The FDA requires more clinical trials and studies of a large-scale nature to be conducted in order to fully understand cannabis and its various effects. Therefore, the lack of research is currently preventing the medical cannabis market from growing, however, large investments are nevertheless seen pouring into the industry to further develop the expansion of the medical cannabis sector. Furthermore, medical institutes are also conducting their own research in order to add credibility to the medical effects of cannabis, while many medical institutes have also backed cannabis as a form of medicinal treatment since it can replace other administered prescription drugs such as opioids. Cannabis, in comparison, is a much safer and cheaper option than opioids because it can be taken in larger and more frequent doses without the side effects of addiction and of brain and liver damage. "Marijuana's medicinal benefits are largely attributed to THC and CBD," said Lynn R. Webster, M.D. Vice President of scientific affairs of PRA Health Sciences, "There is conflicting evidence about how the use of marijuana might affect pain, and whether or not legalizing marijuana might lower the necessity for prescribed opioids. States where it is legal to use medical marijuana do appear to have lowered their use of opioids. There seems to be a correlation between the availability of medical marijuana and a slower rise in the increase of prescribed opioids. While it can't be proven the two are related, the association is strong. The Rockefeller Institute of Government has found that, in states where patients have access to medical marijuana dispensaries, Medicare patients use 14.4% fewer opioids."

Pressure BioSciences, Inc. (OTCQB: PBIO) yesterday announced breaking news that it has, "released a new, short video demonstrating the ability of the Company's proprietary Ultra Shear Technology (UST™) platform to create water-soluble CBD Oil that dissolves instantly, resulting in improved dosing effectiveness, enhanced absorption, and more aesthetically-pleasing products when added to carbonated soft drinks, vitamin-infused sports drinks, and beer.

Link to video: https://youtu.be/gAqFQmsGHcA

In addition to superior aesthetic quality, the Company believes the resulting low nanometer-scale emulsions ("nanoemulsions") of UST-processed CBD Oil will also result in optimized and reproducible bodily absorption, bioavailability, and dosing safety for CBD oil and other UST-processed materials, when compared to many of the processed CBD oils and products that are commercially available today.

Mr. Edgar Ward, President and CEO of NutraLife Biosciences (OTCQB: NLBS), said: "NutraLife manufactures and sells NUTRAHEMPCBD, a line of CBD-infused products that includes creams, sprays, and other products that support daily health and wellness uses. We strive to ensure that our CBD-infused products will always be of the highest quality possible; therefore, we are constantly looking for advanced technologies to continue to improve our manufacturing processes.  After reviewing available data and PBI's videos, we believe methods like PBI's UST platform may enable us to offer products with superior quality and effectiveness."

CBD is a non-psychoactive, oil-soluble compound extracted from the cannabis plant, and is typically marketed dissolved in plant oil. It has been widely reported to offer numerous health benefits from stress and anxiety relief, to decreased muscle, joint, cancer and other pain, reduced inflammation, and to nearly miraculous relief of persistent seizures. However, because CBD is an oil-based product, its ingestion typically results in poor absorption in water-based living systems. There has been enormous interest in the development of truly water-soluble CBD, to achieve efficient absorption and bioavailability from foods and beverages. The market for CBD beverages alone could achieve revenue of $260 million in just the U.S. by 2022 (Bloomberg, September 27, 2018) and much more world-wide. Unfortunately, because of solubility issues, many CBD products on the market today contain an inefficient over-abundance of CBD and/or undesirable chemicals to improve and stabilize its solubility in water. PBI believes that all of these beverages and other CBD-based products could substantially benefit from PBI's Ultra Shear Technology platform, to achieve water solubility and stability from the physics of high-pressure shearing – rather than from dependency upon chemistry and reliance upon use of undesirable chemicals.

Dr. Brad Young, Chief Commercial Officer of PBI, commented: "We are very pleased to now show (in this follow-up video) the ability of our proprietary UST platform to mix CBD oil in water and infuse carbonated soft drinks, vitamin-infused sport drinks, and beer. This latest video further highlights the power of our UST platform to make nanoemulsions and its potential to help nutraceutical and beverage manufacturers make high-quality, oil-based products. With such compelling results to rely on, and with numerous opportunities ahead of us, we intend to accelerate the development of our UST platform to better address what we believe are several multi-billion-dollar markets in nutraceuticals, cosmetics, and food & beverages."

e-mail icon Facebook icon Twitter icon LinkedIn icon Reddit icon
Rate this article: 
Article category: 
Regional Marijuana News: